Zacks Investment Research upgraded shares of SenesTech (NASDAQ:SNES) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning.
According to Zacks, “SenesTech, Inc. developed technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company’s fertility control product candidate, ContraPest(R), will be marketed for use initially in controlling rat infestations. SenesTech, Inc. is based in Flagstaff, Arizona. “
SNES traded up $0.02 during trading on Tuesday, hitting $0.74. The stock had a trading volume of 9,400 shares, compared to its average volume of 818,355. The company has a market capitalization of $19.63 million, a PE ratio of -0.65 and a beta of 2.13. SenesTech has a 12 month low of $0.30 and a 12 month high of $3.87. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.05 and a quick ratio of 4.07.
A hedge fund recently bought a new stake in SenesTech stock. Bank of Montreal Can purchased a new position in SenesTech Inc (NASDAQ:SNES) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 80,000 shares of the company’s stock, valued at approximately $131,000. Bank of Montreal Can owned about 0.48% of SenesTech at the end of the most recent reporting period. 8.03% of the stock is currently owned by institutional investors.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Read More: Return on Investment (ROI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.